



**INTERNATIONAL JOURNAL OF
PHARMACEUTICAL SCIENCES**
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: <https://www.ijpsjournal.com>



Review Article

The Changing Face of Peptic Ulcer Disease : Epidemiology and Management

Vyawahare Gaurav*, Bhise Anjali, Dr. Giri Ashok

Shivlingeshwar College of Pharmacy, Almala, Tq. Ausa Dist. Latur, Maharashtra, India

ARTICLE INFO

Published: 26 Feb 2026

Keywords:

Peptic ulcer disease,
Helicobacter pylori,
Nonsteroidal anti-
inflammatory drugs
(NSAIDs), Epidemiology,
Proton pump inhibitors

DOI:

10.5281/zenodo.18791514

ABSTRACT

Peptic ulcer disease (PUD) has undergone a remarkable transformation over the past several decades because it has changed from a common chronic condition to a disease which doctors now can manage through preventive methods. The historical understanding of PUD as a disease which people developed through stress and dietary habits has changed because scientists now identify Helicobacter pylori infection together with nonsteroidal anti-inflammatory drug (NSAID) usage as the main causes of this condition. The combination of improved sanitation and reduced H. pylori rates in many areas together with effective treatment methods has led to a drop in ulcer cases among younger people. The decline in incidents has been countered by the increasing number of NSAID-related ulcers which occur in elderly people together with patients who have multiple medical conditions. The development of non-invasive testing and endoscopy-based diagnostic methods has resulted in improved patient outcomes through earlier disease detection and precise treatment options. Medical professionals now use proton pump inhibitors together with H. pylori eradication regimens to treat underlying medical conditions instead of just managing symptoms. The medical field still considers bleeding and perforation events as severe complications which affect patients especially those who belong to high-risk demographics. The epidemiology research of peptic ulcer disease provides essential information which helps to develop effective prevention measures and select appropriate medical treatments while it decreases patient suffering. The current situation requires healthcare professionals to adjust their clinical methods while public health systems need to change their strategies for managing PUD.

INTRODUCTION

Peptic ulcer disease (PUD) remains a significant global health concern despite major advances in its understanding and management. Commonly

believed to be a disorder caused by stress and dietary factors and excessive gastric acid production, PUD now exists as a condition which derives from multiple factors with Helicobacter

***Corresponding Author:** Vyawahare Gaurav

Address: Shivlingeshwar College of Pharmacy, Almala, Tq. Ausa Dist. Latur, Maharashtra, India

Email ✉: gauravvyawahare1211@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.



pylori infection and nonsteroidal anti-inflammatory drug (NSAID) usage as its primary causes. The changing understanding of disease causes has brought major changes to both disease transmission patterns and the methods used to treat the condition. The worldwide incidence of PUD has decreased in many regions because people now practice better hygiene and doctors prescribe acid-suppressive medication and they successfully treat *H. pylori* infections, yet the disease still threatens especially to elderly patients and people who suffer from persistent medical conditions.

Peptic ulcer disease now presents different clinical signs. The number of hospital admissions has decreased for patients with uncomplicated ulcers but patients still suffer from serious health issues and death because of ulcer-related bleeding and perforation. The development of endoscopy and non-invasive *H. pylori* testing as diagnostic tools has achieved more precise and earlier identification of medical conditions. The current therapeutic approaches now focus on specific treatments which combine infection eradication with controlled NSAID administration and ongoing risk management instead of treating immediate pain. The article investigates peptic ulcer disease development by studying its changing patterns of occurrence together with its risk factors and current treatment methods which show how this affects medical practice and health regulations.^{[1][6][14][16][17]}

Global Epidemiology of Peptic Ulcer Disease :

The global epidemiology of peptic ulcer disease (PUD) has changed substantially over recent decades because socioeconomic conditions and healthcare access and medical practices have undergone major transformations. The world has experienced a decline in PUD both in prevalence and incidence because high-income countries have implemented better sanitation systems and their

residents have reduced *Helicobacter pylori* transmission and they use effective acid-suppressive therapies. The regions experience a different pattern of younger people who now face lower rates of infection while their population of uncomplicated ulcers has dropped to uncommon levels.

Peptic ulcer disease continues to be a major health problem that affects many low- and middle-income countries because these countries experience high rates of *H. pylori* infection. The combination of overcrowded areas and restricted clean water supplies and the slow process of diagnosing patients leads to ongoing disease spread and increased ulcer development in affected communities. The existing gaps in healthcare facilities throughout the community lead to patients arriving at hospitals too late which increases their chances of developing severe health issues including bleeding and perforation.

The medical field currently experiences an important epidemiological change because doctors now treat more patients with NSAID-induced ulcers especially among senior citizens who live throughout the world. The combination of rising senior populations and greater use of antiplatelet drugs and ongoing treatment for chronic pain has changed the PUD risk factors in areas where *H. pylori* infections have decreased. The worldwide patterns demonstrate how peptic ulcer disease has developed into a complicated medical condition that requires different prevention approaches which should be tailored to specific areas.^{[2][3][4][6][16][17]}

Changing Etiological Factors

The present understanding of peptic ulcer disease (PUD) etiology shows fundamental changes which have created new patterns of clinical symptoms and treatment methods. The medical community



believed until the middle of the twentieth century that peptic ulcers developed from three main causes which included stress and eating patterns and excessive gastric acid production. The discovery of *Helicobacter pylori* revolutionised this understanding, establishing chronic infection as the leading cause of duodenal and a substantial proportion of gastric ulcers worldwide. The improved sanitation practices and antibiotic treatment methods and public health initiatives have led to decreasing *H. pylori* infection rates in various regions, which resulted in lower ulcer rates among younger people.

Current treatment patterns for nonsteroidal anti-inflammatory drugs (NSAIDs) have changed because doctors now prescribe these medications less frequently. Elderly individuals who have cardiovascular and musculoskeletal disorders face their highest risk of developing ulcers through the use of NSAIDs and aspirin together with other antiplatelet medications. The combination of smoking and heavy drinking together with severe bodily stress results in health problems for individuals who have multiple medical conditions.

The development of ulcer disease shows how demographic shifts and healthcare system transformations have changed the treatment methods which result from its transition from infection to medication-induced ulcer disease. Medical professionals must comprehend historical changes in causative factors which have emerged as essential knowledge for creating effective peptic ulcer disease prevention programs and developing custom treatment methods for patients. The research study provides seven sources which prove its arguments.^{[1][2][3][4][5][6][7][14]}

Demographic Shifts in Peptic Ulcer Disease

The demographic profile of peptic ulcer disease PUD shows significant changes throughout recent

decades because of changing disease causes and medical treatment methods and the aging population. The diagnosis of PUD used to occur most frequently in younger and middle-aged men who had a high likelihood of contracting *Helicobacter pylori* infection. The combination of better living conditions and early disease identification and successful treatment methods has resulted in a significant drop in ulcer cases among these communities across multiple areas.

Doctors now understand that peptic ulcer disease primarily affects older adults. The increasing occurrence of this condition in elderly people results from their high usage of nonsteroidal anti-inflammatory drugs and aspirin and all other antiplatelet or anticoagulant drugs. Older patients currently represent a growing percentage of PUD cases while their danger of facing medical emergencies which involve gastrointestinal bleeding and perforation has increased. The gap between men and women who develop PUD has decreased during recent decades. The ulcer rates among men used to be higher than those of women until women started taking NSAIDs more frequently and living longer. The demographic changes that occurred in society demonstrate that people should implement prevention measures which depend on their age and risk factors while using medications according to their specific needs to decrease peptic ulcer disease in present-day societies.^{[2][6][7][14][16]}

Pathophysiology: Traditional vs Modern Concepts :

The traditional understanding of peptic ulcer disease (PUD) is centred on the concept of an imbalance between aggressive factors and mucosal defence. The medical community maintained that gastric acid production together with psychological pressures and consumption of spicy foods and particular lifestyle patterns created



the conditions which led to ulcer development. The model states that ulcers form when acid together with pepsin exceeds the body's ability to protect its gastric and duodenal mucosal surfaces which results in localized tissue damage. The treatment strategies of this model aimed to achieve two goals which included acid neutralization and suppression together with changes in dietary and behavioral patterns.

The current understanding of PUD pathophysiology shows that modern research has developed and improved upon earlier established medical frameworks. The identification of *Helicobacter pylori* showed that persistent bacterial infection causes stomach inflammation which damages mucosal barriers and changes how the stomach produces acid. The widespread prescription of nonsteroidal anti-inflammatory drugs (NSAIDs) established that ulcer formation occurs through two main mechanisms which include impaired prostaglandin production and decreased mucus and bicarbonate output and reduced blood supply to the stomach lining. The research findings demonstrate that stomach lining damage occurs when protective systems fail while stomach acid presents an additional risk factor.

The current understanding of PUD considers both aggressive factors and defensive mechanisms as contributors to the disease's multiple causes. The current approach to treatment has shifted towards three main goals which include treating the root causes of the disease and protecting the stomach lining and decreasing the chances of recurring episodes.^{[3][5][6][14][15]}

Clinical presentations and Evolving patterns :

The clinical presentation of peptic ulcer disease (PUD) has evolved together with the changing patterns of its fundamental causes and the shifting characteristics of its affected patients. The

traditional symptoms of PUD include specific symptoms which doctors used to identify the condition, including epigastric pain, which patients experienced during meals and at night, as well as nausea, and relief through antacid medication. The typical symptoms of duodenal ulcers allowed doctors to make clinical diagnoses by evaluating patient history without needing further tests.

Most patients today show symptoms which do not match common medical patterns or show only minimal signs of their condition. The widespread use of acid-suppressive medications together with the increasing frequency of NSAID-related ulcers has created new symptom patterns which result in medical personnel missing vital symptoms. The elderly population tends to present with non-specific abdominal pain which leads them to seek medical attention only after they develop advanced medical problems. The most prevalent and dangerous medical condition, gastrointestinal bleeding, appears through three main symptoms which include hematemesis and melena and unexplained anaemia.

The number of simple ulcers has decreased, but the rate of advanced cases which involve both bleeding and perforation has increased. Stress-related mucosal disease now occurs more frequently in patients who are critically ill. The development of these clinical patterns demonstrates that doctors should use endoscopic testing to assess patient needs rather than solely depending on their reported symptoms. Medical professionals need to understand how illnesses present differently in order to achieve correct diagnosis and effective treatment which will decrease both ulcer-related health problems and death rates.^{[6][7][14][16]}



Complications and Disease Burden :

Peptic ulcer disease (PUD) creates ongoing health challenges and treatment problems for patients across the globe despite better diagnostic and therapeutic approaches. Ulcer-related bleeding serves as the primary serious complication of the condition which leads to both hospital admissions and blood transfusions and emergency endoscopy procedures. The condition most commonly affects elderly people who use both NSAIDs and antiplatelet and anticoagulant drugs because they experience lower health outcomes.

Perforation represents a medical emergency which occurs less frequently yet results in dangerous health outcomes through its high rate of patient complications and death. The delayed surgical treatment of patients with perforated ulcers results in extended hospital stays which increase their medical costs. Patients who have untreated medical conditions or chronic illnesses still experience gastric outlet obstruction which used to be a common problem.

The complete disease impact of peptic ulcer disease extends beyond its immediate medical complications. The combination of recurring symptoms and continuing medication treatment and the patient's fear of relapse result in decreased quality of life. The healthcare system in low- and middle-income countries suffers from increased disease rates and higher death rates because of delayed medical treatments. The economic impact of peptic ulcer disease includes costs from hospital stays and endoscopic treatments and lost work time. The ongoing challenges demonstrate the need for early disease detection and proper risk assessment methods and preventive measures which will help reduce complications while decreasing the worldwide peptic ulcer disease impact.^{[6][7][12][16][17]}

Diagnostic Approaches in the Modern Era :

Peptic ulcer disease (PUD) diagnostic methods have progressed to their current state which enables medical professionals to determine disease presence and find its cause and assess patient risk. Upper gastrointestinal endoscopy serves as the primary diagnostic method because it allows doctors to see the mucosal surface, verify the existence of ulcers, and perform biopsy procedures that help determine if gastric ulcers contain cancerous tissue. Endoscopic techniques enable medical professionals to detect patients who have severe bleeding risk indicators while they also provide treatment solutions for these cases.

Modern diagnostic pathways use non-invasive testing methods to detect *Helicobacter pylori* infections. Urea breath tests and stool antigen tests offer high sensitivity and specificity and are widely used for initial diagnosis and post-treatment confirmation of eradication. Doctors still use serological testing but they prefer other methods because serological testing cannot determine whether a patient has an ongoing infection or a previous one.

Medical professionals increasingly prefer diagnostic techniques that assess patient risk for diseases. Younger patients without alarm features may be managed using a “test-and-treat” strategy for *H. pylori*, while older patients and those with warning signs undergo prompt endoscopy. Medical professionals use improved imaging methods and laboratory tests to establish diagnoses and evaluate patients for potential complications. The current methods allow medical professionals to identify peptic ulcer disease at an early stage and administer precise treatments which lead to better results for patient care.^{[1][6][11][14]}



Evolution and management strategies :

The development of management techniques for peptic ulcer disease (PUD) has gone through major changes during the last thirty years because medical professionals now understand more about how this condition develops and what causes it. The initial treatment methods of this medical condition aimed to ease symptoms through dietary changes and antacid usage and extended hospital stays. The medical field at that time needed surgical procedures to treat recurring or difficult-to-treat ulcers because all available treatment methods had proven to be ineffective. The development of acid-suppressive medications especially proton pump inhibitors (PPIs) created a significant change in medical treatment because these drugs enabled doctors to achieve quick treatment results. The identification of *Helicobacter pylori* infection followed by its treatment method became the most significant breakthrough in medicine. The introduction of eradication therapy enabled medical professionals to stop treating patients with chronic conditions by permanently curing their illnesses which led to lower recurrence rates and fewer long-term health issues. Medical professionals now focus on controlling NSAID-induced ulcers after *H. pylori*-related conditions have become less common. Medical professionals currently evaluate patient risks while prescribing gastroprotective treatments and selecting medications and choosing different methods to manage pain.

The current medical approach uses treatment methods that target each patient's specific needs while doctors perform endoscopic procedures to handle medical emergencies and mitigate future health risks. The treatment of peptic ulcer disease has progressed through this process to deliver safer and better results which meet patient requirements while decreasing the need for surgical procedures.

Through the medical literature, he conducted research to establish his findings. Across multiple studies that he assessed, he found that his work achieved effective outcomes. ^{[1][4][6][8][11][14]}

Management of Complicated Peptic Ulcer Disease :

The medical emergency of complicated peptic ulcer disease presents a serious threat which leads to both ulcer-related medical problems and death. The most common complications include upper gastrointestinal bleeding and perforation and gastric outlet obstruction which all need immediate treatment through specific medical procedures. The first step of treatment involves hemodynamic stabilization through both fluid resuscitation and blood transfusions which medical staff provide whenever necessary and treatment of coagulation disorders. Medical staff use endoscopic therapy as the primary treatment method to handle bleeding ulcers. Medical professionals use thermal coagulation and hemoclippping and injection therapy methods to achieve hemostasis which they follow up with proton pump inhibitor treatment at high dosages to decrease the chance of rebleeding. The process of identifying and removing *Helicobacter pylori* from the body needs to happen before NSAID and antiplatelet medications can be stopped or changed according to specific requirements. Perforated ulcers usually need emergency surgery as their main treatment method but doctors can choose to treat certain stable patients through non-surgical methods while keeping them under constant observation. Doctors use nasogastric decompression and acid suppression as the first method to treat gastric outlet obstruction while they reserve endoscopic and surgical treatments for patients who do not respond to standard treatment. Medical staff have achieved better patient outcomes through improvements in



endoscopic procedures combined with advancements in critical care and perioperative treatment methods. The medical staff needs to identify the condition at an early stage to provide complete medical treatment which will result in better patient outcomes and less medical complications for patients suffering from complicated peptic ulcer disease. [6][7][12]

Preventive Strategies :

Your training includes data until the end of October in the year 2023. The current era depends on preventive measures to decrease both the initiation of peptic ulcer disease (PUD) and its subsequent complications and recurring episodes. The detection and complete elimination of *Helicobacter pylori* infection represents the most effective method to prevent diseases in regions with high infection rates. Early testing together with proper antibiotic treatment not only assists in ulcer recovery but also decreases the chances of returning ulcers and related medical problems.

The need to prevent NSAID-related ulcers has grown more crucial because patients commonly take these drugs. Prescribing practices require physicians to assess patient risk followed by using the lowest medication dose needed for the shortest time period and prescribing proton pump inhibitors to patients who present high risk. Physicians should use alternative analgesics or selective COX-2 inhibitors whenever they can to reduce the risk of gastrointestinal damage.

People can prevent diseases through lifestyle changes. People who stop smoking and limit their alcohol consumption and do not take medications they do not need will maintain their stomach lining protection. Hospitals should use stress ulcer prophylaxis for patients who have high gastrointestinal bleeding risks. Public health measures and patient education methods together

with regular follow-up procedures strengthen the existing prevention programs. The strategies show a forward-thinking process which assesses dangers to decrease peptic ulcer disease cases while enhancing patient results over extended periods. [1][2][4][6][14]

Special Populations :

The populations who experience peptic ulcer disease (PUD) show unique challenges because their risk factors and clinical symptoms and treatment methods differ from each other. The elderly population stands out as the most at risk group because elderly patients tend to use NSAIDs and aspirin and anticoagulants more than other age groups while displaying unusual signs and dangerous issues which include gastrointestinal bleeding. The presence of various medical conditions together with the use of several medications creates challenges for medical professionals who need to identify and treat this patient category.

People who have chronic illnesses that include cardiovascular disease and renal failure and liver cirrhosis face increased chances of developing ulcers and experiencing negative health effects. The individuals who have these health conditions require appropriate medication selection together with continuous patient monitoring and implementation of security measures. Patients who suffer from critical illnesses will develop stress-related mucosal disease, which requires them to receive acid suppression treatment to stop any potential bleeding.

The medical requirements of pregnant women and pediatric patients require the development of specific diagnostic and therapeutic methods. The health condition of immunocompromised patients who receive extended corticosteroid or chemotherapy treatment will show more severe



disease manifestations and require longer recovery periods. Healthcare providers need to understand this specific patient population so they can deliver better medical solutions which will lead to fewer complications while improving peptic ulcer disease results throughout various healthcare settings. [6][11][14]

Role of the Clinical Pharmacist and Multidisciplinary Care :

The management of peptic ulcer disease (PUD) through multidisciplinary healthcare teams has become essential for treating complex high-risk cases. The framework depends on clinical pharmacists to achieve three goals which include bettering pharmacotherapy results and improving patient protection and treatment efficiency. The experts help to find all medication dangers which include both NSAID misuse and drug interactions and incorrect acid-suppressive therapy dosing. The clinical pharmacists establish *Helicobacter pylori* treatment plans through their knowledge of antibiotic selection and treatment duration and patient adherence and resistance management and side effect control. The medical professionals evaluate patient needs for proton pump inhibitor usage which helps them to stop unnecessary extended treatments and decide when to decrease medication dosages. The hospital pharmacists help doctors decide how to treat stress ulcers and manage anticoagulant use during times of major bleeding.

Multidisciplinary care functions effectively when gastroenterologists work together with surgeons and primary care physicians and nurses and dietitians and pharmacists. The team-based system enables healthcare professionals to execute complete risk assessments which lead to instant medical responses and patient teaching and synchronized follow-up procedures. Multidisciplinary care improves patient treatment

by combining pharmacological knowledge with clinical decision-making which leads to decreased complications and better long-term protection for peptic ulcer disease patients. [6][8][14]

Public Health and Global Challenges :

Peptic ulcer disease (PUD) remains an important public health issue despite significant advances in its prevention and management. Different regions of the world experience different levels of disease burden because people in various parts of the world have unequal access to healthcare and sanitation facilities and educational opportunities. The combination of overcrowding and poor hygiene and limited access to clean water in many low- and middle-income countries leads to ongoing transmission of *Helicobacter pylori* infection which remains prevalent throughout these regions. The healthcare system in resource-limited areas faces difficulty because diagnostic tools and endoscopy services and effective therapies for eradication are not sufficiently available.

The rising antimicrobial resistance problem now presents a major obstacle that hinders successful *H. pylori* eradication efforts throughout the world. High-income countries experience healthcare system problems which arise from three main factors: their growing elderly population and their rising use of NSAID and antiplatelet medications and their need to evaluate acid-suppressive drugs for long-term safety. Public health strategies which include early disease detection and proper medication use and patient education and infection control measures serve as essential tools for decreasing disease burden. The first three steps to achieving equitable healthcare solutions require strengthening healthcare systems and promoting responsible antibiotic usage and tackling social health determinants. The solution to these worldwide challenges needs local and national and



international collaboration to enhance peptic ulcer disease outcomes while minimizing complications. [16][17]

Future Perspectives :

The future of peptic ulcer disease (PUD) treatment will depend on advancements in precision medicine together with early detection methods and public health initiatives. Research studies that examine genetic factors and microbial elements together with immunological components of PUD will create pathways for doctors to develop personalized risk assessments which will guide them in choosing preventive measures and treatment plans for each patient. The development of non-invasive biomarkers and point-of-care testing for both *Helicobacter pylori* and NSAID-induced mucosal damage will improve detection speed and accuracy especially in areas with limited resources.

The presence of antibiotic resistance continues to create significant obstacles which obstruct *H. pylori* eradication efforts. The future of disease management will focus on developing new treatment protocols together with using probiotic supplements and vaccine development to achieve worldwide infection control. The implementation of safer pain relief methods combined with novel gastrointestinal protection solutions will help decrease NSAID-related ulcers among elderly patients who experience multiple health conditions.

Telemedicine and electronic adherence monitoring and artificial intelligence–assisted risk assessment tools which comprise digital health technologies will improve patient education by enabling early medical assistance and continuous monitoring of their health. The combination of clinical progress and effective public health strategies will create the necessary conditions to decrease PUD

prevalence and avoid disease-related complications while achieving better results for patients. The upcoming decades will witness a transformation toward active patient involvement combined with management practices which base their decisions on scientific research. [1][6][8][16]

CONCLUSION :

Peptic ulcer disease (PUD) has experienced a significant evolution during the past several decades because current medical treatments now provide effective methods to prevent and treat this once common and debilitating condition. The understanding of pathophysiology has progressed through research which established *Helicobacter pylori* infection and NSAID use as primary causes of the condition thus changing both diagnosis and treatment methods. The epidemiological patterns show that infection-related ulcers are declining in multiple geographic areas while NSAID-related and age-related ulcers are becoming more common thus demonstrating the requirement for special prevention methods and personalized treatment solutions.

Current treatment methods concentrate on detecting medical conditions at an early stage to eliminate their underlying causes while using acid-suppressive drugs in a controlled manner and building a healthcare team which includes clinical pharmacists who enhance drug treatment results. The three medical complications which include bleeding and perforation and obstruction continue to present major challenges because they are particularly dangerous for both high-risk patients and elderly people thus demonstrating the need for continuous medical observation and urgent treatment.

The field of medicine will benefit from upcoming developments which include precise medicine and non-invasive diagnostic methods and digital health



solutions while public health initiatives worldwide remain essential for handling uneven global disease distribution. The current medical methods for treating peptic ulcer disease (PUD) have developed through research which shows that healthcare professionals should contact patients directly to provide treatments which are based on scientific evidence and proactively control their condition to enhance their health results throughout the world. ^{[1][6][14][16][17]}

REFERENCES

1. Vakil N. (2024). Peptic Ulcer Disease: A Review. *JAMA*, 332(21), 1832–1842. <https://doi.org/10.1001/jama.2024.19094>
2. Chan F. K. (2005). NSAID-induced peptic ulcers and *Helicobacter pylori* infection: implications for patient management. *Drug safety*, 28(4), 287–300. <https://doi.org/10.2165/00002018-200528040-00002>
3. Papatheodoridis, G. V., Sougioultzis, S., & Archimandritis, A. J. (2006). Effects of *Helicobacter pylori* and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. *Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association*, 4(2), 130–142. <https://doi.org/10.1016/j.cgh.2005.10.006>
4. Tang, C. L., Ye, F., Liu, W., Pan, X. L., Qian, J., & Zhang, G. X. (2012). Eradication of *Helicobacter pylori* infection reduces the incidence of peptic ulcer disease in patients using nonsteroidal anti-inflammatory drugs: a meta-analysis. *Helicobacter*, 17(4), 286–296. <https://doi.org/10.1111/j.1523-5378.2012.00942.x>
5. Huang, J. Q., Sridhar, S., & Hunt, R. H. (2002). Role of *Helicobacter pylori* infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. *Lancet* (London, England), 359(9300), 14–22. [https://doi.org/10.1016/S0140-6736\(02\)07273-2](https://doi.org/10.1016/S0140-6736(02)07273-2)
6. Almadi, M. A., Lu, Y., Alali, A. A., & Barkun, A. N. (2024). Peptic ulcer disease. *Lancet* (London, England), 404(10447), 68–81. [https://doi.org/10.1016/S0140-6736\(24\)00155-7](https://doi.org/10.1016/S0140-6736(24)00155-7)
7. Wu, C. Y., Poon, S. K., Chen, G. H., Chang, C. S., & Yeh, H. Z. (1999). Interaction between *Helicobacter pylori* and non-steroidal anti-inflammatory drugs in peptic ulcer bleeding. *Scandinavian journal of gastroenterology*, 34(3), 234–237. <https://doi.org/10.1080/00365529950173618>
8. Kumar, V., Goel, V., Bajaj, S., Garg, K., Bhargava, A., & Dhingra, A. K. (2025). Peptic Ulcer Disease: A Comprehensive Review on Conventional Therapy and Herbal Treatment. *Current drug discovery technologies*, 10.2174/0115701638332791250109044742. Advance online publication. <https://doi.org/10.2174/0115701638332791250109044742>
9. Iijima, K., Kanno, T., Koike, T., & Shimosegawa, T. (2014). *Helicobacter pylori*-negative, non-steroidal anti-inflammatory drug: negative idiopathic ulcers in Asia. *World journal of gastroenterology*, 20(3), 706–713. <https://doi.org/10.3748/wjg.v20.i3.706>
10. Périco, L. L., Emílio-Silva, M. T., Ohara, R., Rodrigues, V. P., Bueno, G., Barbosa-Filho, J. M., Rocha, L. R. M. D., Batista, L. M., & Hiruma-Lima, C. A. (2020). Systematic Analysis of Monoterpenes: Advances and Challenges in the Treatment of Peptic Ulcer Diseases. *Biomolecules*, 10(2), 265. <https://doi.org/10.3390/biom10020265>
11. Kim S. H. (2025). Peptic Ulcer Disease. *The Korean journal of helicobacter and upper*



- gastrointestinal research, 25(1), 13–16.
<https://doi.org/10.7704/kjhugr.2024.0075>
12. Arshad, S. A., Murphy, P., & Gould, J. C. (2025). Management of Perforated Peptic Ulcer: A Review. *JAMA surgery*, 160(4), 450–454.
<https://doi.org/10.1001/jamasurg.2024.6724>
13. Nawaz, Z., Atta, A., Ameen, S., Hussain, S., Yousaf, J., Akbar, A. A., Batool, S. W., Elrefae, A., Ishtiaq, H., Khattak, M. I., & Mirza, T. I. (2025). A Prospective Assessment of Helicobacter pylori Eradication Regimens in Treatment-Naïve Patients With Peptic Ulcer Disease. *Cureus*, 17(10), e93665.
<https://doi.org/10.7759/cureus.93665>
14. Sverdén, E., Agréus, L., Dunn, J. M., & Lagergren, J. (2019). Peptic ulcer disease. *BMJ (Clinical research ed.)*, 367, 15495.
<https://doi.org/10.1136/bmj.15495>
15. Huang, J. Q., Sridhar, S., & Hunt, R. H. (2002). Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. *Lancet* (London, England), 359(9300), 14–22.
[https://doi.org/10.1016/S0140-6736\(02\)07273-2](https://doi.org/10.1016/S0140-6736(02)07273-2)
16. Ren, J., Jin, X., Li, J., Li, R., Gao, Y., Zhang, J., Wang, X., & Wang, G. (2022). The global burden of peptic ulcer disease in 204 countries and territories from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. *International journal of epidemiology*, 51(5), 1666–1676.
<https://doi.org/10.1093/ije/dyac033>
17. Malik TF, Gnanapandithan K, Singh K. Peptic Ulcer Disease. [Updated 2023 Jun 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from:
<https://www.ncbi.nlm.nih.gov/books/NBK534792>

HOW TO CITE: Vyawahare Gaurav, Bhise Anjali, Dr. Giri Ashok, The Changing Face of Peptic Ulcer Disease : Epidemiology and Management, *Int. J. of Pharm. Sci.*, 2026, Vol 4, Issue 2, 4394-4404.
<https://doi.org/10.5281/zenodo.18791514>

